Patents Assigned to Sunesis Pharmaceuticals, Inc.
  • Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
    Patent number: 8518872
    Abstract: Methods of treating, preventing or managing cancers are disclosed. The methods encompass the administration of SNS-595 in combination with a second active agent. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cisplatin, carboplatin, gemcitabine or a combination thereof.
    Type: Grant
    Filed: October 21, 2008
    Date of Patent: August 27, 2013
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventor: Jeffrey A. Silverman
  • Method of preparing (+)-1,4-dihydro-7-[(3,4)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
    Patent number: 8497282
    Abstract: Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: July 30, 2013
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Tamilarasan Subramani, Mohamed Sheik Mohamed Mujeebur Rahuman, Ramar Subbiah
  • Compounds and methods for treatment of cancer
    Patent number: 8470817
    Abstract: Compounds for treating, preventing or managing cancer are disclosed. Also provided are methods for using the compounds in treatment of various cancers. Also provided are methods of treatment using the compounds together with another chemotherapy, radiation therapy, hormonal therapy, biological therapy, or immunotherapy. Pharmaceutical compositions suitable for use in the methods are also disclosed.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: June 25, 2013
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventor: Anantha Sudhakar
  • COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
    Publication number: 20130065858
    Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Application
    Filed: October 22, 2012
    Publication date: March 14, 2013
    Applicants: SUNESIS PHARMACEUTICALS, INC., MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: MILLENNIUM PHARMACEUTICALS, INC., SUNESIS PHARMACEUTICALS, INC.
  • Compounds useful as Raf kinase inhibitors
    Patent number: 8293752
    Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: October 23, 2012
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong Chen, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
    Patent number: 8211904
    Abstract: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: July 3, 2012
    Assignees: Merck, Sharp & Dohme Corp., Sunesis Pharmaceuticals, Inc.
    Inventors: Craig A. Coburn, Melissa S. Egbertson, Samuel L. Graham, Georgia B. McGaughey, Shaun R. Stauffer, Hemaka A. Rajapakse, Philippe G. Nantermet, Shawn J. Stachel, Wenjin Yang, Wanli Lu, Bruce Fahr
  • HETEROARYL BTK INHIBITORS
    Publication number: 20120157442
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 3, 2010
    Publication date: June 21, 2012
    Applicants: SUNESIS PHARMACEUTICALS, INC., BIOGEN IDEC MA INC.
    Inventors: Minna Bui, Patrick Conlon, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Alexey Ishchenko, Tracy J. Jenkins, Gnanasambandam Kumaravel, Doug Marcotte, Noel Powell, Daniel Scott, Art Taveras, Deping Wang, Min Zhong
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20120157443
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 3, 2010
    Publication date: June 21, 2012
    Applicants: SUNESIS PHARMACEUTICALS, INC., BIOGEN IDEC MA INC.
    Inventors: Minna Bui, Patrick Conlon, Julio H. Cuervo, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Tracy J. Jenkins, Gnanasambandam Kumaravel, Alexey A. Lugovskoy, Doug Marcotte, Noel Powell, Daniel Scott, Laura Silvian, Art Taveras, Deping Wang, Min Zhong
  • Novel Ligands and Libraries of Ligands
    Publication number: 20120077711
    Abstract: The present invention provides compounds and libraries of compounds having formula (I): wherein L, n, S and A are defined generally and subsets herein. These compounds and libraries of compounds are useful generally in the drug discovery process.
    Type: Application
    Filed: May 26, 2011
    Publication date: March 29, 2012
    Applicant: SUNESIS PHARMACEUTICALS, INC.
    Inventors: Andrew C. Braisted, Daniel A. Erlanson, Jeffrey W. Jacobs
  • Stable SNS-595 compositions and methods of preparation
    Patent number: 8138202
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: March 20, 2012
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • 1,8-naphthyridine compounds for the treatment of cancer
    Patent number: 8124773
    Abstract: Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: February 28, 2012
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Daniel C. Adelman, Marc J. Evanchik, Anantha Sudhakar, Jeffrey William Jacobs, Jeffrey A. Silverman
  • Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
    Patent number: 8114887
    Abstract: The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: February 14, 2012
    Assignees: Merck, Sharp & Dohme Corp., Sunesis Pharmaceuticals, Inc.
    Inventors: James C. Barrow, Craig A. Coburn, Melissa S. Egbertson, Georgia B. McGaughey, Melody A. McWherter, Lou Anne Neilson, Kenneth E. Rittle, Harold G. Selnick, Shaun R. Stauffer, Zhi-Qiang Yang, Wenjin Yang, Wanli Lu, Bruce Fahr
  • AURORA KINASE INHIBITORS
    Publication number: 20110293745
    Abstract: The present invention provides Compound 1, solid forms thereof, compositions thereof, as Aurora kinase inhibitor for use as an oncology agent. The present invention also provides synthetic methods of preparing Compound 1 and intermediates thereto.
    Type: Application
    Filed: March 16, 2009
    Publication date: December 1, 2011
    Applicant: SUNESIS PHARMACEUTICALS, INC.
    Inventors: Ute Hoch, Jeffrey A. Silverman, Daniel C. Adelman
  • Methods of using SNS-595
    Patent number: 7989468
    Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: August 2, 2011
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Daniel C. Adelman, Jeffrey A. Silverman
  • Therapeutic combinations comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
    Patent number: 7968565
    Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: June 28, 2011
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Michelle Arkin, Jennifer Hyde, Duncan Walker, Jasmin Wright
  • Heterocyclic compounds useful as RAF kinase inhibitors
    Patent number: 7968536
    Abstract: The present invention provides compounds useful as inhibitors of protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: June 28, 2011
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Jennifer Cossrow, Bing Guan, Alexey Ishchenko, John Howard Jones, Gnanasambandam Kumaravel, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
    Patent number: 7932257
    Abstract: The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: wherein one of is a double bond, as valency permits; and R2, R4, X1A, X2A, X1B, X2B, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: April 26, 2011
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Johan D. Oslob, Chul Hyun Yu
  • Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease
    Publication number: 20100298342
    Abstract: The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: September 4, 2007
    Publication date: November 25, 2010
    Applicants: MERCK & CO., INC., SUNESIS PHARMACEUTICALS, INC.
    Inventors: Melissa S. Egbertson, Shaun R. Stauffer, Craig A. Coburn, James C. Barrow, Lou Anne Neilson, Jenny M. Wai, Wenjin Yang, Wanli Lu, Bruce Fahr
  • Pharmaceutical compositions of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
    Patent number: 7829577
    Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: November 9, 2010
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., Sunesis Pharmaceuticals, Inc.
    Inventors: Masaru Higaki, Satoshi Nakao
  • Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
    Patent number: 7767687
    Abstract: The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: n, R1, R2, R3, R4, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., RAF), and thus are useful, for example, for the treatment of RAF mediated diseases.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: August 3, 2010
    Assignees: Biogen Idec MA Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Johan D. Oslob, Jiang Zhu, Kenneth Barr, Jennifer Cossrow, Brian Raimundo, Hiroko Tanaka